Revenue declined year-over-year, but operating and net income rose sharply in H1 2025, driven by the Bio-Chemical segment. Major R&D and plant investments continue, with strong cash reserves and new supply contracts supporting future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.